PL3030232T3 - Gojenie ran poprzez autologiczną mobilizację komórek macierzystych - Google Patents

Gojenie ran poprzez autologiczną mobilizację komórek macierzystych

Info

Publication number
PL3030232T3
PL3030232T3 PL14791563.1T PL14791563T PL3030232T3 PL 3030232 T3 PL3030232 T3 PL 3030232T3 PL 14791563 T PL14791563 T PL 14791563T PL 3030232 T3 PL3030232 T3 PL 3030232T3
Authority
PL
Poland
Prior art keywords
stem cell
wound healing
autologous stem
cell mobilization
healing via
Prior art date
Application number
PL14791563.1T
Other languages
English (en)
Inventor
Zhaoli Sun
George Melville Williams
Qing Lin
Original Assignee
Medregen, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medregen, Llc filed Critical Medregen, Llc
Publication of PL3030232T3 publication Critical patent/PL3030232T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14791563.1T 2013-04-29 2014-04-29 Gojenie ran poprzez autologiczną mobilizację komórek macierzystych PL3030232T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361816827P 2013-04-29 2013-04-29
US201361907624P 2013-11-22 2013-11-22
PCT/US2014/035793 WO2014179266A2 (en) 2013-04-29 2014-04-29 Wound healing via autologous stem cell mobilization

Publications (1)

Publication Number Publication Date
PL3030232T3 true PL3030232T3 (pl) 2022-11-07

Family

ID=51844093

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14791563.1T PL3030232T3 (pl) 2013-04-29 2014-04-29 Gojenie ran poprzez autologiczną mobilizację komórek macierzystych

Country Status (9)

Country Link
US (2) US10945993B2 (pl)
EP (2) EP3030232B1 (pl)
CN (2) CN105658217B (pl)
DK (1) DK3030232T3 (pl)
ES (1) ES2927803T3 (pl)
HU (1) HUE059749T2 (pl)
PL (1) PL3030232T3 (pl)
SI (1) SI3030232T1 (pl)
WO (1) WO2014179266A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
JP7010817B2 (ja) * 2015-07-16 2022-01-26 メドレジェン,リミティド ライアビリティ カンパニー 組織損傷の治療に有用な医薬組成物
CN107064137A (zh) * 2016-12-28 2017-08-18 钟叔平 一种无创的皮肤创面采样观察及分析方法
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
AU2021377219A1 (en) 2020-11-10 2023-06-29 Medregen, Llc Formulations, methods, kits, and dosage forms
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CN121941496A (zh) * 2023-07-10 2026-04-28 美德睿臻有限公司 下调和上调通路的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5365948A (en) 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
JP2003523940A (ja) 1999-05-11 2003-08-12 オーソ−マクネイル ファーマシューティカル インコーポレイテッド エリスロポエチン投与の薬物速度論的および薬力学的モデリング
MXPA03002325A (es) 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
PL372705A1 (pl) 2001-09-12 2005-07-25 Anormed Inc. Sposoby syntezy enancjomerycznie czystych związków z dwoma skondensowanymi pierścieniami podstawionych grupą aminową
US20050058622A1 (en) 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
EP1663216B1 (en) 2003-08-29 2011-11-02 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
WO2005039621A1 (ja) * 2003-10-27 2005-05-06 Keio University G-csfを含む線維芽細胞動員剤及び創傷治療剤
JP5135795B2 (ja) 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
WO2006123226A2 (en) 2005-05-18 2006-11-23 De Villiers, Malan An inhibitor of mtor for inhibiting the formation of scar tissue
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
WO2007087367A2 (en) 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
US20070292401A1 (en) 2006-06-20 2007-12-20 Harmon Alexander M Soft tissue repair and regeneration using stem cell products
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
EP2039348A1 (en) 2007-09-21 2009-03-25 Jürgen Schliefelbein Cosmetic preparation and method to obtain a somatic stem cell preparation
WO2009074807A2 (en) * 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
WO2009094456A2 (en) 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
US8383124B2 (en) 2008-03-12 2013-02-26 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
US20110135651A1 (en) 2008-08-19 2011-06-09 Children's Hospital Medical Center Method and composition for enhancing hematopoietic stem cell mobilization
US20110166078A1 (en) 2008-09-15 2011-07-07 Endotis Pharma Oligosaccharide compounds for use in mobilising stem cells
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
WO2010093802A2 (en) 2009-02-11 2010-08-19 The General Hospital Corporation Therapeutic method for increasing pancreatic beta cell mass
US20100226894A1 (en) 2009-03-09 2010-09-09 Alex Wah Hin Yeung Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood
HRP20210334T1 (hr) * 2009-12-11 2021-04-02 Medregen, Llc Metode liječenja u kojima se primjenjuju mobilizatori matičnih stanica i imunosupresivna sredstva
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2012078746A2 (en) 2010-12-07 2012-06-14 The Johns Hopkins University Compositions and methods for mobilizing stem cells

Also Published As

Publication number Publication date
CN113663077A (zh) 2021-11-19
US12048687B2 (en) 2024-07-30
ES2927803T3 (es) 2022-11-11
WO2014179266A9 (en) 2016-04-21
EP4091609A1 (en) 2022-11-23
EP3030232A2 (en) 2016-06-15
CN113663077B (zh) 2024-03-15
DK3030232T3 (da) 2022-10-10
CN105658217B (zh) 2021-03-19
US20210251954A1 (en) 2021-08-19
US10945993B2 (en) 2021-03-16
CN105658217A (zh) 2016-06-08
HUE059749T2 (hu) 2022-12-28
US20160106710A1 (en) 2016-04-21
WO2014179266A2 (en) 2014-11-06
EP3030232B1 (en) 2022-07-06
SI3030232T1 (sl) 2022-11-30
EP3030232A4 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
IL245573A0 (en) cell
GB201302468D0 (en) Stem cell product
GB2516340B (en) Wound dressings
GB201303814D0 (en) Battery structure
PL2966327T3 (pl) Ulepszona konstrukcja zaworów trójdrożnych
HUE059749T2 (hu) Sebgyógyítás autológ õssejt-mobilizáció útján
ZA201508186B (en) Methods and compositions for wound healing
EP2980873A4 (en) CRYOSTAT
GB201310031D0 (en) Cell
SG11201601408PA (en) Stem cell modulation ii
GB2514561B (en) Overhearing
GB201310730D0 (en) New structure
TWM476247U (en) Dehumidifier structure
GB2518246B (en) Greenhouse
PL3021877T3 (pl) Opatrunek na ranę
GB2511577B (en) Carrying structure
TWM476256U (en) Two-part stick structure
GB201311829D0 (en) Tweezers
GB201311905D0 (en) Bandage
GB201303217D0 (en) Bridges Research Application - BRA
AU2013900590A0 (en) App Staff
TWM476584U (en) Wound dressings
TWM476735U (en) Umbrella structure
TWM476968U (en) Meteorology lamp
GB201317589D0 (en) Cell